The decision paves the way for broader digital asset adoption in the UK London, 6 June 2025 – 21Shares, one of the world’s leading issuers of cryptocurrency exchange-traded products (ETPs) and the first to list crypto ETNs on the London Stock Exchange (LSE), welcomes the Financial Conduct Authority’s (FCA) announcement today proposing to lift the ban on offering crypto exchange-traded notes (cETNs) to UK retail investors. The proposal aims to support innovation and competitiveness in the UK’s digital asset ...

Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET.NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET. A live webcast of the fireside chat will be available on the Ev ...

COLUMBIA, Md., June 06, 2025 (GLOBE NEWSWIRE) -- Rekor Systems, Inc. (NASDAQ: REKR) (the "Company), a leader in developing and implementing state-of-the-art roadway intelligence technology, today announced a transformative deployment with a Sun Belt state transportation agency. As part of a new state initiative to upgrade its planning and operations capabilities, Rekor will deploy 150 Rekor Discover® systems under a one-year Data-as-a-Service contract valued at $1.2 million. The Company expects all 150 syst ...

Second Quarter Fiscal 2025 Summary(All comparisons are year-over-year unless otherwise noted) Revenue of $37.4 million, compared to $22.4 million, an increase of approximately 67%Gross loss of $(9.4) million compared to $(7.1) million, an increase of approximately 33%Loss from operations of $(35.8) million compared with $(41.4) million, a decrease of approximately 13%Net loss per share was $(1.79) compared with $(2.18), a decrease of approximately 18%Backlog of $1.26 billion, compared to $1.06 billion, an i ...

TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- BE Resources Inc. (TSX-V: BER.H) (“BE Resources” or the “Company”) announces that, further to the Company’s press release dated March 6, 2025, the Company settled C$361,361.23 of debt owed to certain creditors of the Company in consideration for the issuance of 5,559,399 common shares of the Company (the “Shares”) at a deemed price of C$0.065 per Share (the “Debt Settlement”). The Company expects that the proposed Debt Settlement will assist the Company in preservi ...

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, today provides an update regarding the status of its securities in connection with its previously announced delay in filing its interim financial statements for the quarter ended March 31, 2025.‎ As disclosed on May 30, 2025, the Company was unable to meet the deadline to file its interim financial report, management’s discussion ...

| Series | RIKV 25 0917 | | | RIKV 25 1217 | | | --- | --- | --- | --- | --- | --- | | Settlement Date | | 06/11/2025 | | | 06/11/2025 | | Total Amount Allocated (MM) | | 1,800 | | | 19,400 | | All Bids Awarded At (Price / Simple interest) | 97.947 / | 7.700 | 96.115 | / | 7.699 | | Total Number of Bids Received | | 6 | | | 22 | | Total Amount of All Bids Received (MM) | | 2,300 | | | 20,000 | | Total Number of Successful Bids | | 5 | | | 20 | | Number of Bids Allocated in Full | | 5 | | | 20 | | Lowest Pri ...

Core Insights - ProPhase Labs Inc. has established a Clinical Science Advisory Board to facilitate the clinical adoption and commercialization of its BE-Smart molecular test for esophageal disease, aiming to set a new standard in early detection and management of esophageal cancer risk [1][10] - The BE-Smart test is positioned to capture a target market of approximately $7 - $14 billion, based on the 7 million endoscopies performed annually in the U.S. for patients at risk of esophageal cancer, with a reimbursement goal of $1,000 - $2,000 per test [3] Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on innovative healthcare solutions, including Whole Genome Sequencing and diagnostic developments [11] - The company aims to revolutionize healthcare through actionable insights and is committed to executional excellence and smart diversification [11] Advisory Board Composition - The advisory board includes Dr. Joe Abdo, the inventor of the BE-Smart test, and Mr. James McCullough, founder and CEO of Renalytix, both of whom bring extensive experience in molecular oncology and diagnostic technologies [2][9] - Additional experts will be added to the advisory board to support the initial commercial launch of BE-Smart [2] Product Features and Advantages - BE-Smart offers a unique approach by measuring real-time protein activity, which captures dynamic biological signals of disease progression, requiring only a single 10 µm FFPE biopsy section [3][4] - The test integrates into existing endoscopy and pathology workflows, providing results in under 7 days without added complexity for healthcare providers [3] Clinical Utility - BE-Smart can stratify risk for patients with GERD and Barrett's Esophagus, addressing limitations of current diagnostic tools [4] - The test's design is scalable and cost-efficient, making it an attractive option for clinicians and healthcare systems [4] Competitive Landscape - Other technologies like TissueCypher and EsoGuard have established momentum in esophageal diagnostics, paving the way for broader adoption of molecular tools [5] - BE-Smart builds on this progress by offering a next-generation approach that combines real-time biological precision with streamlined clinical integration [5] Intellectual Property - ProPhase Labs has secured exclusive patents covering proprietary methods for detecting and analyzing eight key proteins critical for esophageal adenocarcinoma progression, providing a competitive advantage in the molecular diagnostics market [6] Clinical Validation - The latest clinical validation manuscript for BE-Smart is under review at the Journal of Clinical Gastroenterology and Hepatology, with a preprint expected soon [7][8]

Company Overview - Neo Performance Materials Inc. is a manufacturer of advanced industrial materials that enhance efficiency and sustainability, including magnetic powders, rare earth magnets, and specialty chemicals [5] - The company operates in three segments: Magnequench, Chemicals & Oxides, and Rare Metals, with a global presence including manufacturing facilities in China, Germany, Canada, Estonia, Thailand, and the UK, as well as a dedicated R&D center in Singapore [5] Market Transition - Neo Performance Materials has upgraded to trade on the OTCQX Best Market from the Pink market, which is a significant step for enhancing transparency and accessibility for U.S. investors [1][3] - The company will begin trading under the symbol "NOPMF" on the OTCQX, allowing U.S. investors to access real-time financial disclosures [2] Strategic Positioning - The CEO of Neo Performance Materials emphasized that the upgrade to OTCQX enhances the company's visibility and accessibility for U.S. investors, positioning it well to meet the growing demand for critical materials in electrification and modern technologies [4] - The company aims to broaden its shareholder base while executing its strategic priorities to drive long-term value [4]

Core Viewpoint - Nurix Therapeutics is set to present new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) at the European Hematology Association Congress, highlighting the company's focus on targeted protein degradation medicines for cancer treatment [1][5]. Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [5]. - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on innovative drug design [5]. - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline, supported by a fully AI-integrated discovery engine [5]. Clinical Trial Information - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule degrader of BTK, currently evaluated in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [4]. - The ongoing clinical trial can be accessed for additional information at clinicaltrials.gov (NCT05131022) [4]. Upcoming Presentations - The company will host a webcast conference call on June 12, 2025, to discuss the new data from the Phase 1 clinical trial, which will be presented at the EHA2025 [1][2]. - Presentations at EHA2025 include findings on the clinical activity and safety of bexobrutideg in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia, scheduled for June 13 and June 14, respectively [6].